First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback